PMID- 29575464
OWN - NLM
STAT- MEDLINE
DCOM- 20180629
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 5
DP  - 2018 May
TI  - Tumor necrosis factor-alpha induces prostate cancer cell migration in lymphatic 
      metastasis through CCR7 upregulation.
PG  - 1524-1531
LID - 10.1111/cas.13586 [doi]
AB  - Understanding the mechanism of lymph node metastasis, a poor prognostic sign for 
      prostate cancer, and the further dissemination of the disease is important to 
      develop novel treatment strategies. Recent studies have reported that C-C 
      chemokine receptor 7 (CCR7), whose ligand is CCL21, is abundantly expressed in 
      lymph node metastasis and promotes cancer progression. Tumor necrosis factor-alpha 
      (TNF-alpha) is chronically produced at low levels within the tumor microenvironment. 
      The aim of this study was to determine whether TNF-alpha promotes prostate cancer 
      dissemination from metastatic lymph nodes through activation of the CCL21/CCR7 
      axis. First, human prostate cancer cells were determined to express both TNF-alpha 
      and CCR7. Second, low concentrations of TNF-alpha were confirmed to induce CCR7 in 
      prostate cancer cells through phosphorylation of ERK. Finally, CCL21 was found to 
      promote the migration of prostate cancer cells through phosphorylation of the 
      protein kinase p38. Our results suggest that TNF-alpha leads to the induction of CCR7 
      expression and that the CCL21/CCR7 axis might increase the metastatic potential 
      of prostate cancer cells in lymph node metastasis.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Maolake, Aerken
AU  - Maolake A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
AD  - Departments of Cancer Genetics and Urology, Roswell Park Cancer Institute, 
      Buffalo, NY, USA.
FAU - Izumi, Kouji
AU  - Izumi K
AUID- ORCID: 0000-0002-8480-9100
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Natsagdorj, Ariunbold
AU  - Natsagdorj A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Iwamoto, Hiroaki
AU  - Iwamoto H
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadomoto, Suguru
AU  - Kadomoto S
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Makino, Tomoyuki
AU  - Makino T
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Naito, Renato
AU  - Naito R
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Shigehara, Kazuyoshi
AU  - Shigehara K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadono, Yoshifumi
AU  - Kadono Y
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Hiratsuka, Kaoru
AU  - Hiratsuka K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Wufuer, Guzailinuer
AU  - Wufuer G
AD  - Hematology Department, People's Hospital of Xinjiang Uyghur Autonomous Region, 
      Xinjiang, China.
FAU - Nastiuk, Kent L
AU  - Nastiuk KL
AD  - Departments of Cancer Genetics and Urology, Roswell Park Cancer Institute, 
      Buffalo, NY, USA.
FAU - Mizokami, Atsushi
AU  - Mizokami A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University 
      Graduate School of Medical Science, Kanazawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180429
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (CCL21 protein, human)
RN  - 0 (CCR7 protein, human)
RN  - 0 (Chemokine CCL21)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Chemokine CCL21/physiology
MH  - Humans
MH  - Lymphatic Metastasis
MH  - MAP Kinase Signaling System/physiology
MH  - Male
MH  - Prostatic Neoplasms/*pathology
MH  - Receptors, CCR7/genetics/*physiology
MH  - Tumor Necrosis Factor-alpha/*pharmacology
MH  - Up-Regulation
MH  - p38 Mitogen-Activated Protein Kinases/physiology
PMC - PMC5980342
OTO - NOTNLM
OT  - C-C chemokine receptor type 7
OT  - lymph node
OT  - metastasis
OT  - prostate cancer
OT  - tumor necrosis factor-alpha
EDAT- 2018/03/27 06:00
MHDA- 2018/06/30 06:00
PMCR- 2018/05/01
CRDT- 2018/03/26 06:00
PHST- 2017/12/28 00:00 [received]
PHST- 2018/03/12 00:00 [revised]
PHST- 2018/03/17 00:00 [accepted]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/06/30 06:00 [medline]
PHST- 2018/03/26 06:00 [entrez]
PHST- 2018/05/01 00:00 [pmc-release]
AID - CAS13586 [pii]
AID - 10.1111/cas.13586 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 May;109(5):1524-1531. doi: 10.1111/cas.13586. Epub 2018 Apr 29.